General Information of Drug (ID: DMURVE8)

Drug Name
Elacridar Drug Info
Synonyms
Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
119373
CAS Number
CAS 143664-11-3
TTD Drug ID
DMURVE8
VARIDT Drug ID
DR00573

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Multidrug resistance protein 1 (ABCB1) TT3OT40 MDR1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Multidrug resistance protein 1 (ABCB1) DTT ABCB1 7.009 6.988 7.442 8.135
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Multidrug resistance protein 1 (ABCB1) DTT ABCB1 3.12E-33 -0.83 -1.04
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002537)
2 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J Med Chem. 2008 Dec 11;51(23):7602-13.